Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi said it would spend close to 700 million euros ($754 million) more on drugs development next year, specifying for the first time an increase in costs that roiled investors and triggered a sell-off in the stock in late October.

Sanofi to boost drug development spend by 700 mln euros in 2024

Sarclisa ® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it faces investor pressure after abandoning 2025 margin targets while boosting research and development spending.

Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline

R&D Day Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology Details strong pipeline including Sanofi's record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 ‘pipeline-in-a-product' assets with a potential of over €5 billion peak sales Strategic transformation through R&D features potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si intended to address unmet patient needs in markets with low penetration of advanced therapies Enhanced R&D focus aims to deliver a 50% increase in Phase 3 trials in 2024 and 2025 as well as 25 mid- to late-stage read-outs over the next 2 years Ambition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of Dupixent and Vaccines Paris, December 6, 2023. Today Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

PARIS--(BUSINESS WIRE)--AQEMIA announces a major multi-year collaboration of $140 million with Sanofi.

AQEMIA Announces a Major Multi-year Collaboration of $140 Million With Sanofi

Sanofi's CEO is under pressure to tell investors how much more he will spend on research and development (R&D) and what the likely pay-offs will be, as he seeks to boost a pipeline of future drugs and restore shareholder trust.

Sanofi CEO under pressure to woo investors after spending shock

Caterpillar

Prologis

Here are three undervalued stocks with promising growth potential and high-quality A-rated balance sheets. It's just one of three incredible opportunities that combine to create a 16% annual return potential for the next decade, 350%, almost 3X more than the S&P. These are wide moat industry legends, blue-chip bargains hiding in plain sight.

Buy These 3 Deep Value, A-Rated Dividend Stocks Hand Over Fist

PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease. As announced on October 4th, 2023, under the terms of the agreemen.

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

Limited pipeline catalysts until 2025 mean a "show me" story status. Higher R&D costs and uncertainty for the future. A new spin-off in the consumer division with no 2025 profitability targets. Sanofi is still attractive, but we are lowering our target price.

Sanofi: A Shift In The Story

Regeneron Pharmaceuticals

Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales

Sanofi plans to file for U.S. approval of wider use of its anti-inflammatory drug Dupixent against "smoker's lung", also known as COPD, after a second large trial showed significant benefits.

Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win

Dupixent ® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

AstraZeneca

The CDC's move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise in some parts of the country.

CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage

The U.S. Centers for Disease Control and Prevention said on Thursday it has released more than 77,000 additional doses of Sanofi and AstraZeneca's respiratory syncytial virus (RSV) drug Beyfortus.

CDC releases 77,000 additional doses of Sanofi-AstraZeneca's RSV drug

Amgen

Gilead Sciences

Merck

Pfizer

While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and likely 2024.

5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now

French prosecutors have opened a preliminary investigation into multinational pharmaceutical company Sanofi over possible market manipulation.

French prosecutors investigating Sanofi over possible market manipulation

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results.

Pfizer and Sanofi shares fall, which one to scoop up?

Sanofi's third-quarter results weren't great, and the company announced a business separation. The biotech will lower its operating income margin target for 2025, which scared off many investors.

This Stock Just Dropped By 15%: Is It a Buy?

CAMBRIDGE, Mass. , Nov. 2, 2023 /PRNewswire/ -- Sanofi has announced the winners of its 2023 Health Equity Accelerator Awards, honoring 10 nonprofit organizations that exemplify the company's ambition to provide equitable access to healthcare using innovative solutions for hard-to-solve health disparities.

Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities

Ligand Pharmaceuticals

SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million.

Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million

Nationwide storytelling movement to showcase diverse voices of the type 1 diabetes community, including internationally recognized stars Usher, Robin Arzón, and Adam Schefter, to share experiences and encourage people to get screened The 1 Pledge movement commences with surround-sound event in New York City's Times Square; continues throughout the year with events and social storytelling Screening for type 1 diabetes can detect the disease before noticeable symptoms arise1; people can pledge to get themselves and their family screened at The1Pledge.com BRIDGEWATER, N.J. , Nov. 1, 2023 /PRNewswire/ -- Sanofi, a leader in diabetes care, today launched "The 1 Pledge" movement, a nationwide education campaign urging families to get screened for type 1 diabetes so that those who will eventually be affected by the disease can begin to prepare as soon as possible.

Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.

AbbVie

Bristol-Myers

Johnson & Johnson

Eli Lilly

The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.

Investor patience tested as pharmaceutical stocks take a tumble

MeiraGTx Holdings plc

MeiraGTx Holdings PLC (NASDAQ:MGTX) shares gained more than 25% after it announced Sanofi SA (ADR) (NYSE:SNY), a pharma giant best known for its vaccines, is purchasing 4 million of the gene company's shares at a price of $7.50 per share for a total $30 million investment. MeiraGTx stock was up 25.4% at US$4.64 late morning on Monday, while Sanofi shares gained 3.5% at US$44.63.

MeiraGTx shares take off on $30M investment by Sanofi

Chevron

Microsoft

Advanced Micro Devices

Comcast

Cisco Systems

Datadog

L3Harris

Southwest Airlines

Newell Brands

ON Semiconductor

Valley National

Vertex Pharmaceuticals

Western Digital

Here are some of the tickers on Jim's radar for Monday, Oct. 30, taken directly from his reporter's notebook:

Here are 16 stocks Jim Cramer is watching, including Microsoft, Chevron, Southwest

Shares of MeiraGTx Holdings PLC MGTX, -4.88% jumped 14% premarket on Monday after the gene therapy company announced that French drugmaker Sanofi SNY, -19.13% has made a $30 million investment.

News for Sanofi Stock (SNY)